everyone. good and Shawn, morning, Thanks,
a to in We’re off strong start XXXX.
physician Our health services. prior driven system business year, by strong base double and performance across digit grew to compared lab
minimal the how us at disease this shared my testing. of transaction Later Investor oncology strategy month of how we remarks residual well fast-growing describe announced Day molecular we acquisition and the in morning Oncology. category the positions and genomics This is in it aligned to last I’ll Haystack
share revenue were X%. base turning supported billion. per first on a reported of And grew a volume $X.X growth nearly revenues on the business quarter. were business Now, Total adjusted earnings basis to and base basis. XX%, Total $X.X $X.XX by an
the in growth our the points of all in some at return volume customer highlights look saw experienced The in let's We test number range continued delaying a quarter. strong care quarter. pandemic. from to care This people across are to suggests a requisition Now, after to the a the system base care faster broad business test types, across of of we for per categories. growth returning the healthcare clinical routine during more
with overall faster health ongoing to the This Health our plan the quality, trend to saving thereby actively lower-cost than steer to patients also efforts to volumes health continue partner business. and plan for to members. like grow money plans directly related is employers Quest, providers plan, high
revenues quarter, would book said at X% the with from X% During offerings. new board wins business base and to CAGR, Day, approximately about At of health X%. our Investor this professional we lab systems having reference the and first services grew we're grow across in success
testing. helping Some of manage announced Pennsylvania in reference to include: supply Tower its chain we're Health addition February, that these highlights we laboratory performing in in
Light center. Health services labs began of nine all large up system for ramp where Light Northern relationship hospital PLS Maine, a its the providing Northern are quarter. Our in to and its we health cancer is in integrated
We also closed Lights our acquisition assets. of outreach lab Northern
flow NewYork-Presbyterian, we months. earlier acquisition outreach Finally, is the services this volumes into laboratory with Clifton, This new acquisition with in the month. we completed Jersey strategic our to New test last our laboratory completed starting six third
our health pipeline of quarter, remains including additional we new the system enter many business strong, PLS opportunities. second As
an Haystack early testing. or our residual words company, Oncology. planned disease, is Now acquisition MRD I'd announcement like this to Haystack minimal focused regarding say a our oncology about stage of on few morning
or technology The recurring that developed Johns genomics has highly technology pioneers. licensed a Hopkins cancer where from was biopsy by was residual liquid tumor and it detect cells. developed DNA sensitive Haystack can from circulating
Day for and cancer surgery was be recur. potential At treated Quest’s cancer for that missed must patients the diagnosis also in mature strong areas roll monitored some initial and years the a assay. therapy with Investor because treatment. and about Most in may that of cancer we talked and following selection there’s This always TSOXXX position our leading play will screening is we
in will combined technology, category. growing MRD and biopsy position in a sequencing liquid leading Haystack strengths to now pathology our roll screening, a play us with fast
We initially and lung to on year. start revenue and focus expect cancers colorectal, to generating breast next
area to recent Quest the proprietary of developments Alzheimer's diagnostics. brain of blood AD-Detect in We risk the which advanced saw other we year, are helps test we disease. growth last test. us Alzheimer's launched encouraged health In strong assess also by largely attribute This
are to We Alzheimer's help us the of risk recommendations tests assess to additional inherited now personalized provide and lower risk. introducing
growth our strong B screening saw advanced cardiometabolic our C and testing. in also genetics, We and hepatitis blood-based portfolio; prenatal tuberculosis
hepatitis CDC's for the decision recommend to by B. one-time encouraged are We recent screening
health, consumer long our menopause to we continue services, including menu to with and In test new COVID testing. add
and We the consumers their testing, a provided also well. volume care year-over-year offerings in utilize health by growth genetics consumer panel as physician. the launch In our new plan generated months, as general strong we a allergy coming as to to complement
Invigorate. Turning to
annual achieving target. We savings toward our on productivity are well our way X%
the Here many are examples contributors. among some recent
sites In patient We are closing of improving network. locations. to volume services smaller draw some efficiency adding staff we're higher and cases, our the larger,
walk-ins At our be register schedule easier the check-in for at time, it seen same service. and through making to we're
features new both collections process, adding are improves We and which the pre-registration convenience. patient to
collections our During of relied we the COVID-XX and pandemic, test logistics supplement heavily team's third-party on to specimens. other own
these the which for logistics operations. on we have are our dependence eases, labor and volumes will market vendors, our savings generate reducing declined COVID-XX
our labor models post-pandemic drive staffing reflect Finally, lab our volumes to continuing enhance to productivity. we're network across and total
we functions. to our quarter. As of taken actions support in the and to beginning the continue manage help closely we've said will we before, second have corporate The cost start margins
an are you lab schedule give where to update on cuts. clinical Medicare like with I'd Finally, we fee
Act, strongly were of We reintroduction XXXX. Laboratory Access or SALSA. cuts fix As support for PAMA you Saving bipartisan recent the legislation the know, Services through the Congress to in to PAMA suspended
association on working with importance a driving stop at lab the lab on are to our cuts, We SALSA aimed services. for campaign through of congressional advocacy outreach trade
Now on our more to our performance I'll it Sam? provide Sam turn XXXX details and over guidance. updated to
